Vokanamet is a combination medication primarily composed of two active pharmaceutical ingredients: canagliflozin and metformin hydrochloride. It is designed as a film-coated tablet to manage specific health conditions.
Understanding Vokanamet's Active Ingredients
Vokanamet is a dual-component medication used for the treatment of type 2 diabetes mellitus. Its precise composition combines an SGLT2 inhibitor with a biguanide, offering a synergistic approach to blood glucose control.
The qualitative and quantitative composition for Vokanamet 50 mg/850 mg film-coated tablets is detailed as follows:
| Component | Quantity (per film-coated tablet) |
|---|---|
| Canagliflozin | 50 mg (derived from canagliflozin hemihydrate) |
| Metformin Hydrochloride | 850 mg |
This specific formulation ensures that patients receive precise doses of both active compounds in a single tablet.
Role of Each Component
- Canagliflozin: This ingredient belongs to a class of drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. It works by causing the kidneys to remove sugar from the body through the urine, thereby helping to lower blood glucose levels.
- Metformin Hydrochloride: As a biguanide, metformin works by reducing the amount of glucose produced by the liver, decreasing glucose absorption from the diet, and increasing the body's sensitivity to insulin. It is a cornerstone medication for type 2 diabetes.
By combining these two distinct mechanisms of action, Vokanamet offers a comprehensive approach to managing blood sugar in adults with type 2 diabetes, particularly when diet and exercise alone, or metformin alone, do not provide adequate control. The European Medicines Agency (EMA) provides further regulatory information on such pharmaceutical products.
